🔎 Trials Near Me

Home › Obesity › NCT07784725

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

RecruitingPhase 3

A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity Without Type 2 Diabetes Mellitus (SELENE 1)

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Males \& females (inclusive of all gender identities) age ≥18 years
* BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with at least one of the following weight related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, heart failure, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, osteoarthritis of the knee, or stress urinary incontinence
* Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation
* History of at least one self-reported unsuccessful attempt to lose body weight in their lifetime

Exclusion Criteria:

* Obesity primarily caused by other endocrine disorders
* History of Type 1 or Type 2 Diabetes Mellitus, HbA1c ≥6.5% (48 mmol/mol), and/or treatment with glucose-lowering agent(s) within 3 months prior to Screening
* Significant hepatobiliary disease and/or any of the following results at Screening:

  * ALT ≥ 3.0 × ULN
  * AST ≥ 3.0 × ULN
  * TBL \> 1.5 × ULN (except for cases of known Gilbert's Syndrome)
* Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation.

About the study

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

What is being tested

Sponsor: AstraZeneca · Participants: 2,500 · Started: Aug 19, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07784725

Locations in the U.S.

AlabamaResearch Site, Dothan (Not yet recruiting)
Research Site, Huntsville (Not yet recruiting)
ArizonaResearch Site, Mesa (Not yet recruiting)
CaliforniaResearch Site, Escondido (Not yet recruiting)
FloridaResearch Site, Clearwater (Not yet recruiting)
Research Site, Jacksonville (Not yet recruiting)
GeorgiaResearch Site, Stockbridge (Not yet recruiting)
IllinoisResearch Site, Champaign (Not yet recruiting)
Research Site, Chicago (Not yet recruiting)
IowaResearch Site, Ames (Not yet recruiting)
MichiganResearch Site, Troy (Not yet recruiting)
MissouriResearch Site, Jefferson City (Not yet recruiting)
Research Site, Kansas City (Not yet recruiting)
MontanaResearch Site, Butte (Not yet recruiting)
NevadaResearch Site, Las Vegas (Not yet recruiting)
New JerseyResearch Site, Jersey City (Not yet recruiting)
New YorkResearch Site, Cortland (Not yet recruiting)
North CarolinaResearch Site, Statesville (Not yet recruiting)
North DakotaResearch Site, Fargo (Not yet recruiting)
OhioResearch Site, Columbus (Not yet recruiting)
OklahomaResearch Site, Tulsa (Not yet recruiting)
OregonResearch Site, Portland (Not yet recruiting)
PennsylvaniaResearch Site, Philadelphia (Not yet recruiting)
Research Site, Smithfield (Not yet recruiting)
TennesseeResearch Site, Kingsport (Not yet recruiting)
TexasResearch Site, Houston (Not yet recruiting)
Research Site, San Antonio (Not yet recruiting)
Research Site, Sugar Land (Not yet recruiting)
Research Site, Waco (Not yet recruiting)
UtahResearch Site, Salt Lake City (Not yet recruiting)
VirginiaResearch Site, Arlington (Not yet recruiting)
WashingtonResearch Site, Seattle (Not yet recruiting)

Conditions

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.